Yoshiyama Takashi, Ito Kunihiko, Ogata Hideo, Mitarai Satoshi, Hoshino Hitoshi, Okumura Masao, Aman Kumiko, Aono Akio, Wada Masako
Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association (JATA).
Kekkaku. 2004 Dec;79(12):717-24.
To investigate the reasons of acquiring drug resistance among MDR TB cases and to learn lessons for the prevention of acquiring of drug resistance.
Retrospective review of 159 MDR TB cases who were treated at Fukujuji Hospital from 1990 January to 2003 August.
We found that among 159 cases, 48 cases were infected with multidrug resistant M. tuberculosis bacilli, 35 cases acquired drug resistance, 7 cases were with the history of tuberculosis treatment before 1970 only, and that remaining 69 cases were difficult to evaluate because of the lack of informations on previous drug susceptibility tests. Among 35 cases that acquired drug resistance, the drug susceptibility test patterns before becoming MDR TB were categorized as follows: 12 HR susceptible, 18 H resistant R susceptible, 3 R susceptible (H unknown), and 2 H susceptible R resistant. The factors that may have influenced to acquire MDR were lack of modification of the regimen after knowing drug resistance among H resistant R susceptible cases, and defaulting among cases that were not evaluated (15/69) and H resistant R susceptible cases (3/18).
Control of MDR TB needs to be strengthened. Proper drug susceptibility test, proper choice of drugs at the beginning of treatment and modification of treatment after knowing drug susceptibility test results are important for the prevention of MDR TB. Ensuring patient adherence to treatment is important in the medical institutions where drug susceptibility test is not properly done, in particular, for H resistant R susceptible cases, and guidance to these institutions by the public health centers should be intensified.
调查耐多药结核病(MDR TB)病例获得耐药性的原因,并吸取预防耐药性产生的经验教训。
回顾性分析1990年1月至2003年8月在福住寺医院接受治疗的159例MDR TB病例。
我们发现,在159例病例中,48例感染了耐多药结核分枝杆菌,35例获得了耐药性,7例仅有1970年以前的结核病治疗史,其余69例因缺乏既往药敏试验信息而难以评估。在35例获得耐药性的病例中,成为MDR TB之前的药敏试验模式分类如下:12例对异烟肼(H)和利福平(R)敏感,18例H耐药R敏感,3例R敏感(H未知),2例H敏感R耐药。可能影响获得耐多药的因素包括:H耐药R敏感病例在知晓耐药性后未调整治疗方案;未评估病例(15/69)和H耐药R敏感病例(3/18)中存在治疗中断。
需要加强耐多药结核病的控制。进行恰当的药敏试验、治疗开始时正确选择药物以及在知晓药敏试验结果后调整治疗方案对于预防耐多药结核病很重要。在未正确进行药敏试验的医疗机构中,确保患者坚持治疗很重要,特别是对于H耐药R敏感病例,公共卫生中心应加强对这些机构的指导。